Wanbury Ltd
Wanbury Ltd (WANBURY) last reported results for the quarter ended Jun 2025, with sales of ₹163 crore and net profit of ₹13 crore. The stock last traded at ₹194, a market capitalisation of ₹678 crore, on a P/E of 15.8. Over the past 52 weeks the stock has ranged between ₹162 and ₹360. Figures are as of 6 Oct 2026 and are not real time.
Wanbury Ltd share price and key metrics
- Current price
- ₹194
- Market cap
- ₹678 cr
- Stock P/E
- 15.8
- Book value
- ₹18.1
- ROE
- 76.5%
- ROCE
- 36.6%
- Dividend yield
- 0.00%
- 52w high / low
- 360/162
Metrics as of 6 Oct 2026. Not real time.
Track Wanbury Ltd
Cruxal reads every Wanbury Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Wanbury Ltd growth and returns
- 10 Years
- 9%
- 5 Years
- 10%
- 3 Years
- 5%
- TTM
- 12%
- 10 Years
- 26%
- 5 Years
- 31%
- 3 Years
- 80%
- TTM
- 60%
- 10 Years
- 13%
- 5 Years
- 17%
- 3 Years
- 37%
- 1 Year
- -26%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 77%
Wanbury Ltd quarterly results
In the quarter ended Jun 2025, sales were ₹163 cr, up 24.4% from ₹131 cr a year earlier. Net profit was ₹13 cr, up 1200.0% year on year.
| ₹ crore | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 144 | 146 | 139 | 131 | 161 | 133 | 172 | 163 |
| Expenses | 127 | 124 | 121 | 120 | 141 | 120 | 142 | 139 |
| Operating profit | 17 | 21 | 18 | 11 | 20 | 14 | 30 | 24 |
| OPM % | 12% | 15% | 13% | 8% | 12% | 10% | 17% | 15% |
| Other income | 1 | 1 | 26 | 1 | 2 | 1 | 2 | 0 |
| Interest | 8 | 8 | 7 | 8 | 10 | 10 | 9 | 8 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| Profit before tax | 7 | 10 | 34 | 1 | 8 | 1 | 19 | 14 |
| Tax % | -2% | -0% | 1% | 0% | 2% | 5% | -6% | 1% |
| Net profit | 7 | 10 | 34 | 1 | 8 | 1 | 20 | 13 |
| EPS (₹) | 2.25 | 3.14 | 10.27 | 0.32 | 2.45 | 0.37 | 6.18 | 4.10 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Wanbury Ltd annual results
| ₹ crore | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 420 | 432 | 370 | 391 | 367 | 392 | 511 | 485 | 557 | 600 | 630 |
| Operating profit | 33 | 19 | -68 | 16 | 23 | 18 | 36 | 26 | 73 | 80 | 88 |
| OPM % | 8% | 4.3% | -18% | 4.1% | 6% | 4.7% | 7% | 5% | 13% | 13% | 14% |
| Net profit | -7 | 62 | -32 | -25 | 64 | -13 | 81 | -10 | 56 | 31 | 43 |
| EPS (₹) | -3.58 | 26.71 | -13.49 | -10.48 | 25.79 | -5.04 | 24.94 | -3.18 | 17.09 | 9.32 | 13.10 |
TTM is the trailing twelve months to the most recent quarter.
Wanbury Ltd balance sheet
| ₹ crore | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 20 | 23 | 24 | 24 | 25 | 25 | 33 | 33 | 33 | 33 |
| Reserves | -209 | -176 | -208 | -233 | -168 | -181 | -56 | -66 | -5 | 26 |
| Borrowings | 362 | 300 | 250 | 260 | 190 | 192 | 100 | 95 | 116 | 179 |
| Other liabilities | 215 | 265 | 207 | 236 | 232 | 253 | 276 | 241 | 199 | 176 |
| Total liabilities | 388 | 412 | 273 | 286 | 279 | 289 | 353 | 304 | 343 | 414 |
| Fixed assets | 180 | 186 | 178 | 172 | 164 | 167 | 167 | 167 | 167 | 201 |
| CWIP | 14 | 10 | 10 | 9 | 14 | 11 | 2 | 2 | 3 | 5 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 193 | 216 | 84 | 105 | 101 | 111 | 183 | 135 | 174 | 208 |
| Total assets | 388 | 412 | 273 | 286 | 279 | 289 | 353 | 304 | 343 | 414 |
As reported by the company. Total assets equal total liabilities by construction.
Wanbury Ltd cash flow
| ₹ crore | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 43 | 43 | 32 | 30 | 44 | 17 | 41 | 20 | 4 | 26 |
| Cash from investing | -20 | -13 | -1 | -3 | 64 | 8 | 1 | -9 | -17 | -51 |
| Cash from financing | -28 | -27 | -33 | -27 | -108 | -17 | -29 | -32 | 15 | 26 |
| Net cash flow | -5 | 3 | -2 | -0 | -0 | 7 | 13 | -21 | 2 | 1 |
| Free cash flow | 22 | 29 | 30 | 25 | 36 | 12 | 42 | 7 | -10 | -23 |
| CFO / operating profit | 129% | 234% | -49% | 188% | 188% | 97% | 113% | 76% | 6% | 33% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Wanbury Ltd operating ratios
| Per year | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 12% | 57% | -1% | 26% | 31% | 27% | 46% | 21% | 61% | 37% |
| Debtor days | 65 | 71 | 29 | 41 | 50 | 32 | 45 | 52 | 59 | 70 |
| Inventory days | 69 | 63 | 27 | 36 | 25 | 41 | 60 | 26 | 43 | 47 |
| Days payable | 172 | 260 | 174 | 209 | 253 | 221 | 218 | 179 | 196 | 172 |
| Cash conversion cycle | -38 | -125 | -118 | -131 | -177 | -148 | -113 | -101 | -94 | -55 |
| Working capital days | -123 | -185 | -277 | -254 | -236 | -251 | -153 | -152 | -40 | 4 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Wanbury Ltd shareholding pattern
Promoters held 43.01% at Jun 2026, up from 39.63% at Jun 2025. FIIs 0.89% and DIIs 0.06%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 39.77% | 39.76% | 39.76% | 39.63% | 43.09% | 43.08% | 43.01% | 43.01% |
| FIIs | 1.02% | 0.84% | 1.55% | 1.59% | 0.82% | 0.72% | 0.59% | 0.89% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.06% |
| Public | 59.21% | 59.40% | 58.68% | 58.79% | 56.08% | 56.21% | 56.39% | 56.04% |
| No. of shareholders | 17,199 | 17,999 | 17,889 | 17,894 | 17,717 | 17,261 | 16,732 | 17,174 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Wanbury Ltd corporate filings
- Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.Company Updatelow impact
- Wanbury files new Drug Master File (DMF) in South Africa for Tramadol HC1 APICompany Updatelow impact
Cruxal's analysis: Wanbury Ltd announced the filing of a new DMF in South Africa for Tramadol HC1 API on…
Read the full analysis - Trading Window Closure for the Quarter ended 30th September, 2026.Insider Trading / SASTlow impact
- Wanbury Limited announces successful passing of all resolutions at 38th Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Wanbury Limited has concluded its 38th Annual General Meeting held on September 24, 2026…
Read the full analysis - Wanbury Limited announces outcome of 38th Annual General Meeting regarding board re-appointment and cost auditor ratificationCompany Updatelow impact
Cruxal's analysis: Wanbury Limited has concluded its 38th Annual General Meeting, where shareholders…
Read the full analysis - Wanbury Limited concludes 38th Annual General Meeting with approval of all resolutionsAGM/EGMlow impact
Cruxal's analysis: Wanbury Limited has successfully concluded its 38th Annual General Meeting, where…
Read the full analysis - Wanbury Ltd announces 38th Annual General Meeting via VC/OAVMCompany Updatelow impact
Cruxal's analysis: Wanbury Ltd has issued a newspaper publication regarding the scheduling of its 38th…
Read the full analysis - Wanbury Limited announces 38th Annual General Meeting and Book Closure datesCorp. Actionlow impact
Cruxal's analysis: Wanbury Limited has formally notified the stock exchanges that its 38th Annual General…
Read the full analysis - Wanbury Limited announces 38th Annual General Meeting and release of 2025-26 Annual ReportOtherslow impact
Cruxal's analysis: Wanbury Limited has filed its Annual Report for the financial year 2025-26 and issued the…
Read the full analysis - Wanbury Limited Reports Strong FY 2025-26 Financials and Announces 38th AGMAGM/EGMhigh impact
Cruxal's analysis: Wanbury Limited has released its Annual Report for FY 2025-26, reporting a significant…
Read the full analysis - Wanbury Ltd schedules 38th Annual General Meeting for September 24, 2026Company Updatelow impact
Cruxal's analysis: Wanbury Ltd has issued a newspaper publication notice regarding its 38th Annual General…
Read the full analysis - Wanbury Ltd receives EDQM approval for Rivaroxaban API and USFDA DMF clearancesCompany Updatemedium impact
Cruxal's analysis: Wanbury Ltd has secured European Directorate for the Quality of Medicines (EDQM) approval…
Read the full analysis - Wanbury Limited Q1 FY27 Results: Margin Contraction Due to Input Costs Offset by Strategic Debt Refinancing and Regulatory WinsCompany Updatemedium impact
Cruxal's analysis: Wanbury Limited reported Q1 FY27 revenue of 165.6 crore, a modest 1.5% YoY growth, while…
Read the full analysis - Wanbury Limited Reports Q1 FY27 Financial Results, Debt Refinancing, and Promoter Pledge ReleaseBoard Meetinghigh impact
Cruxal's analysis: Wanbury Limited reported Q1 FY27 revenue of 165.58 crore, showing a modest YoY increase…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.